Division of Cardiovascular Medicine, Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65212, USA.
Am J Ther. 2011 Jul;18(4):280-7. doi: 10.1097/MJT.0b013e3181c6c0d2.
Heart failure (HF) is a leading cause of morbidity and mortality. Appropriate medical therapy using angiotensin converting enzyme inhibitors and beta-blockers improves outcomes in HF, whereas the role of digoxin is still not clearly defined. Digoxin is currently recommended for patients with HF who are symptomatic despite standard therapy and for controlling the ventricular rate in atrial fibrillation. Digoxin is a time-tested drug that accounts for 20 million drug prescriptions annually in the United States. It has favorable hemodynamic effects for patients with HF and atrial tachyarrhythmias. We conducted a systematic literature search for the current indications for digoxin. Despite extensive research and safety data, the literature suggests that digoxin is underused in clinical settings. Citing the literature where available, our review highlights the various clinical settings where digoxin is indicated. Despite difficulties with designing prospective studies in acute HF settings and lack of outcomes data, we believe that digoxin will continue to serve an important role in optimizing care in certain acute and chronic cardiac conditions.
心力衰竭(HF)是发病率和死亡率的主要原因。适当的医学治疗,使用血管紧张素转换酶抑制剂和β受体阻滞剂,可改善 HF 的预后,而地高辛的作用仍未明确界定。地高辛目前推荐用于 HF 患者,尽管有标准治疗,但仍有症状,以及控制心房颤动时的心室率。地高辛是一种经过时间考验的药物,在美国每年有 2000 万份药物处方。它对 HF 和房性心动过速患者有良好的血液动力学作用。我们进行了系统的文献检索,以了解地高辛的当前适应证。尽管进行了广泛的研究和安全性数据,但文献表明,地高辛在临床环境中使用不足。我们的综述引用了可用的文献,强调了地高辛在各种临床情况下的适应证。尽管在急性 HF 环境中设计前瞻性研究存在困难,并且缺乏结局数据,但我们认为地高辛将继续在某些急性和慢性心脏疾病的优化治疗中发挥重要作用。